Oct. 2 (Bloomberg) -- DaVita Inc., a provider of kidney-dialysis services, said the U.S. Justice Department ended an investigation into the company and took no action.
The inquiry, begun by the U.S. attorney in St. Louis in March 2005, covered topics including financial relationships with doctors and joint ventures, the Denver-based company said in a statement today. Prosecutors also looked into the administration and billing of Epogen, a drug for anemia, DaVita said.
DaVita cooperated with the investigation, which ended without the government filing charges, demanding payments or seeking changes in company policies, according to the statement.
DaVita fell 0.2 percent to close at $103.44 yesterday in New York Stock Exchange trading.
Peter Grauer, the chairman of Bloomberg LP, serves on the board of DaVita.
To contact the reporter on this story: Phil Serafino in Paris at firstname.lastname@example.org